Home > Journals > Minerva Medica > Past Issues > Minerva Medica 2022 June;113(3) > Minerva Medica 2022 June;113(3):424-35

CURRENT ISSUE
 

JOURNAL TOOLS

Publishing options
eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as
Share

 

REVIEW  CHRONIC OBSTRUCTIVE PULMONARY DISEASE Free accessfree

Minerva Medica 2022 June;113(3):424-35

DOI: 10.23736/S0026-4806.22.07957-5

Copyright © 2022 EDIZIONI MINERVA MEDICA

language: English

Identification of biomarkers in COPD by metabolomics of exhaled breath condensate and serum/plasma

Debora PARIS 1, Letizia PALOMBA 2, Annabella TRAMICE 1, Lorenzo MOTTA 3, Salvatore FUSCHILLO 4, Mauro MANISCALCO 4, Andrea MOTTA 1

1 Institute of Biomolecular Chemistry, National Research Council, Pozzuoli, Naples, Italy; 2 Department of Biomolecular Sciences, Carlo Bo University, Urbino, Pesaro-Urbino, Italy; 3 Section of Radiology, Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, Ferrara, Italy; 4 Division of Pulmonary Rehabilitation, IRCCS Maugeri Clinical Scientific Institutes, Telese Terme Institute, Telese Terme, Benevento, Italy



Chronic obstructive pulmonary disease (COPD) is the third cause of death worldwide, presenting poor long-term outcomes and chronic disability. COPD is a condition with a wide spectrum of clinical presentations because its pathophysiological determinants relate to tobacco smoke, genetic factors, alteration of several metabolic pathways, and oxidative stress. Consequently, patients present different phenotypes even with comparable degrees of airflow limitation. Because of the increasing social and economic costs of COPD, a growing attention is currently paid to “omics” techniques for more personalized treatments and patient-tailored rehabilitation programs. In this regard, the systematic investigation of the metabolome (i.e., the whole set of endogenous molecules) in biomatrices, namely metabolomics, has become indispensable for phenotyping respiratory diseases. The metabolomic profiling of biological samples contains the small molecules produced during biological processes and their identification and quantification help in the diagnosis, comprehension of disease outcome and treatment response. Exhaled breath condensate (EBC), plasma and serum are biofluids readily available, with negligible invasiveness, and, therefore, suitable for metabolomics investigations. In this paper, we describe the latest advances on metabolomic profiling of EBC, plasma and serum in COPD patients.


KEY WORDS: Pulmonary disease, chronic obstructive; Metabolomics; Biomarkers

top of page